⏳ Final hours! Save up to 60% OFF InvestingProCLAIM SALE

Insiders Buying Phathom Pharmaceuticals And 2 Other Stocks

Published 12/04/2023, 12:57
Updated 12/04/2023, 14:10
© Reuters.  Insiders Buying Phathom Pharmaceuticals And 2 Other Stocks
REIT
-

Benzinga - Although US stocks closed mixed on Tuesday, there were a few notable insider trades.

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.

Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform.

Phathom Pharmaceuticals

  • The Trade: Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) Chief Operating Officer Azmi Nabulsi acquired a total of 10,000 shares an average price of $8.26. To acquire these shares, it cost around $82.6 thousand. The company’s Director also purchased the company’s shares.
  • What’s Happening: Phathom Pharmaceuticals announced a regulatory update, noting "favorable feedback following meeting with the FDA allows for planned resubmission of erosive esophagitis new drug application this quarter."
  • What Phathom Pharmaceuticals Does: Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases.
Strawberry Fields REIT
  • The Trade: Strawberry Fields REIT, Inc. (NYSE: STRW) CEO Moishe Gubin acquired a total of 3,500 shares at an average price of $5.90. To acquire these shares, it cost around $20.65 thousand.
  • What’s Happening: Strawberry Fields REIT recently announced 2022 year-end operating results.
  • What Strawberry Fields REIT Does: Strawberry Fields REIT Inc is a self-managed and self-administered company that specializes in the acquisition, ownership and triple-net leasing of skilled nursing facilities and other post-acute healthcare properties.
Don’t forget to check out our premarket coverage here

American Strategic Investment

  • The Trade: American Strategic Investment Co. (NYSE: NYC) 10% owner New York City Advisors LLC bought a total of 3,926 shares at an average price of $11.56. To acquire these shares, it cost around $45.4 thousand.
  • What’s Happening: New York City REIT recently posted Q4 core FFO of $0.11.
  • What American Strategic Investment Does: American Strategic Investment Co formerly New York City REIT Inc is formed to invest its assets in office properties located in the five boroughs of New York City, with a focus on Manhattan.
Check This Out: Fear & Greed Index Remains In 'Greed Zone Ahead Of March Inflation Data

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.